65 related articles for article (PubMed ID: 35477053)
1. COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection.
Murillo-Zamora E; Trujillo X; Huerta M; Ríos-Silva M; Guzmán-Esquivel J; Benites-Godínez V; Ochoa-Castro MR; Guzmán-Solórzano JA; Mendoza-Cano O
Int J Infect Dis; 2022 Jul; 120():142-145. PubMed ID: 35477053
[TBL] [Abstract][Full Text] [Related]
2. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
Ann Intern Med; 2022 May; 175(5):674-681. PubMed ID: 35157493
[TBL] [Abstract][Full Text] [Related]
3. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021.
Cavanaugh AM; Spicer KB; Thoroughman D; Glick C; Winter K
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1081-1083. PubMed ID: 34383732
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
Kang M; Yi Y; Li Y; Sun L; Deng A; Hu T; Zhang J; Liu J; Cheng M; Xie S; Luo M; Jiang J; Jiang Y; Tang S; He J
Ann Intern Med; 2022 Apr; 175(4):533-540. PubMed ID: 35099990
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
Malhotra S; Mani K; Lodha R; Bakhshi S; Mathur VP; Gupta P; Kedia S; Sankar J; Kumar P; Kumar A; Ahuja V; Sinha S; Guleria R; ; Dua A; Ahmad S; Sathiyamoorthy R; Sharma A; Sakya T; Gaur V; Chaudhary S; Sharma S; Madan D; Gupta A; Virmani S; Gupta A; Yadav N; Sachdeva S; Sharma S; Singh S; Pandey A; Singh M; Jhurani D; Sarkar S; Lokade AK; Mohammad A; Pandit S; Dubey R; Singh AK; Gohar N; Soni D; Bhattacharyya A; Rai S; Tummala S; Gupta I; Shukla S
JAMA Netw Open; 2022 Jan; 5(1):e2142210. PubMed ID: 34994793
[TBL] [Abstract][Full Text] [Related]
7. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
9. Decreased risk of COVID-19 pneumonia in children and adolescents during the Delta variant emergence.
Murillo-Zamora E; Trujillo X; Huerta M; Ríos-Silva M; Baltazar-Rodríguez LM; Guzmán-Esquivel J; Benites-Godínez V; Ortega-Ramírez AD; Mendoza-Cano O
Public Health; 2022 Mar; 204():9-11. PubMed ID: 35085915
[TBL] [Abstract][Full Text] [Related]
10. Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection.
Murillo-Zamora E; Mendoza-Cano O; Delgado-Enciso I; Hernandez-Suarez CM
Public Health; 2021 Apr; 193():113-115. PubMed ID: 33774512
[TBL] [Abstract][Full Text] [Related]
11. First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence.
Murillo-Zamora E; Trujillo X; Huerta M; Ríos-Silva M; Lugo-Radillo A; Baltazar-Rodríguez LM; Mendoza-Cano O
Public Health; 2022 Jun; 207():105-107. PubMed ID: 35594806
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
14. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.
Bozio CH; Grannis SJ; Naleway AL; Ong TC; Butterfield KA; DeSilva MB; Natarajan K; Yang DH; Rao S; Klein NP; Irving SA; Dixon BE; Dascomb K; Liao IC; Reynolds S; McEvoy C; Han J; Reese SE; Lewis N; Fadel WF; Grisel N; Murthy K; Ferdinands J; Kharbanda AB; Mitchell PK; Goddard K; Embi PJ; Arndorfer J; Raiyani C; Patel P; Rowley EA; Fireman B; Valvi NR; Griggs EP; Levy ME; Zerbo O; Porter RM; Birch RJ; Blanton L; Ball SW; Steffens A; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron M; Gaglani M; Thompson MG; Stenehjem E
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1539-1544. PubMed ID: 34735425
[TBL] [Abstract][Full Text] [Related]
15. Effect of vaccination on SARS-CoV-2 reinfection risk: a case-control study in the Republic of Cyprus.
Quattrocchi A; Tsioutis C; Demetriou A; Kyprianou T; Athanasiadou M; Silvestros V; Mamais I; Demetriou CA; Theophanous F; Soteriou S; Gregoriadou C; Anastasiou E; Kolios P; Ηaralambous C; Gregoriou I; Kalakouta O; Nikolopoulos G
Public Health; 2022 Mar; 204():84-86. PubMed ID: 35193032
[TBL] [Abstract][Full Text] [Related]
16. Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees.
Kojima N; Roshani A; Brobeck M; Baca A; Klausner JD
Int J Infect Dis; 2022 May; 118():21-23. PubMed ID: 35151852
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials.
Sobczak M; Pawliczak R
Ann Clin Microbiol Antimicrob; 2022 Jul; 21(1):32. PubMed ID: 35786399
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers.
Bayhan GI; Guner R
Hum Vaccin Immunother; 2022 Dec; 18(1):2020017. PubMed ID: 35172694
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 Pneumonia in Fully Vaccinated Adults during the Dominance of the Omicron Sublineages BA.1.1 and BA.2 in Mexico.
Murillo-Zamora E; Trujillo X; Huerta M; Riós-Silva M; Guzmán-Esquivel J; Bricio-Barrios JA; Mendoza-Cano O; Lugo-Radillo A
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
